These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
52 related articles for article (PubMed ID: 34433362)
21. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112 [TBL] [Abstract][Full Text] [Related]
22. Reduced Environmental Impact of the Reusable Respimat Hänsel M; Bambach T; Wachtel H Adv Ther; 2019 Sep; 36(9):2487-2492. PubMed ID: 31317391 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness of inhalation technique assessment service for patients with Respimat® inhaler. Rossi V; Salimäki J; Sandler C; Airaksinen M; Kauppi P Pulm Pharmacol Ther; 2021 Dec; 71():102077. PubMed ID: 34534672 [TBL] [Abstract][Full Text] [Related]
24. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Miravitlles M; Montero-Caballero J; Richard F; Santos S; Garcia-Rivero JL; Ortega F; Ribera X Int J Chron Obstruct Pulmon Dis; 2016; 11():407-15. PubMed ID: 27013871 [TBL] [Abstract][Full Text] [Related]
25. Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland. Tschacher A; Cadus C; Schildge S; Diedrich JP; Chhajed PN; Leuppi-Taegtmeyer AB; Leuppi JD Curr Med Res Opin; 2021 Nov; 37(11):2019-2033. PubMed ID: 34433362 [TBL] [Abstract][Full Text] [Related]
26. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Hodder R; Price D Int J Chron Obstruct Pulmon Dis; 2009; 4():381-90. PubMed ID: 19888356 [TBL] [Abstract][Full Text] [Related]
27. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease. Kässner F; Hodder R; Bateman ED Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628 [TBL] [Abstract][Full Text] [Related]
28. Tiotropium versus placebo for chronic obstructive pulmonary disease. Karner C; Chong J; Poole P Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525 [TBL] [Abstract][Full Text] [Related]
29. Clinical effectiveness of the Respimat inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. Ram FS; Carvallho CR; White J Int J Chron Obstruct Pulmon Dis; 2011; 6():129-39. PubMed ID: 21468167 [TBL] [Abstract][Full Text] [Related]
30. Use of Respimat Soft Mist inhaler in COPD patients. Anderson P Int J Chron Obstruct Pulmon Dis; 2006; 1(3):251-9. PubMed ID: 18046862 [TBL] [Abstract][Full Text] [Related]
31. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? Dahl R; Kaplan A BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909 [TBL] [Abstract][Full Text] [Related]
32. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD]. Henriet AC; Marchand-Adam S; Mankikian J; Diot P Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393 [TBL] [Abstract][Full Text] [Related]
33. The Respimat Soft Mist Inhaler, a Novel Inhaled Drug Delivery Device. Perriello EA; Sobieraj DM Conn Med; 2016; 80(6):359-64. PubMed ID: 27509644 [TBL] [Abstract][Full Text] [Related]
34. Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease. Ferguson GT; Dalby RN Postgrad Med; 2018 Aug; 130(6):515-522. PubMed ID: 29972656 [TBL] [Abstract][Full Text] [Related]
35. Tiotropium Respimat(®) Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Keating GM Drugs; 2014 Oct; 74(15):1801-16. PubMed ID: 25300412 [TBL] [Abstract][Full Text] [Related]
36. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences. Ninane V; Vandevoorde J; Cataldo D; Derom E; Liistro G; Munghen E; Peché R; Schlesser M; Verleden G; Vincken W Respir Med; 2015 Nov; 109(11):1430-8. PubMed ID: 26439177 [TBL] [Abstract][Full Text] [Related]
37. The Respimat Iwanaga T; Tohda Y; Nakamura S; Suga Y Clin Drug Investig; 2019 Nov; 39(11):1021-1030. PubMed ID: 31377981 [TBL] [Abstract][Full Text] [Related]
38. Requirements, Strengths and Weaknesses of Inhaler Devices for COPD Patients from the Expert Prescribers' Point of View: Results of the EPOCA Delphi Consensus. García-Río F; Soler-Cataluña JJ; Alcazar B; Viejo JL; Miravitlles M COPD; 2017 Dec; 14(6):573-580. PubMed ID: 28891722 [TBL] [Abstract][Full Text] [Related]
39. A review of the development of Respimat Soft Mist Inhaler. Dalby R; Spallek M; Voshaar T Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496 [TBL] [Abstract][Full Text] [Related]
40. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent? Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]